Propanc Biopharma IncOTC Pink - Current Information:PPCB
- LAST PRICE0.0003
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0003/ 2,213
- Ask / Lots0.0004/ 181,974
- Open / Previous Close0.0003 / 0.0003
- Day Range
- 52 Week Range
- Volume9,276,767
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PPCB |
|---|---|---|
| 10:00 ET | 16666 | 0.00025 |
| 10:02 ET | 166 | 0.00025 |
| 10:08 ET | 165 | 0.0003 |
| 10:47 ET | 1981050 | 0.0003 |
| 11:02 ET | 1500000 | 0.0003 |
| 01:11 ET | 1028720 | 0.0003 |
| 01:38 ET | 471280 | 0.0003 |
| 01:42 ET | 1000000 | 0.00025 |
| 01:44 ET | 1000000 | 0.00025 |
| 01:45 ET | 500000 | 0.00025 |
| 01:47 ET | 450000 | 0.0003 |
| 01:49 ET | 550000 | 0.00025 |
| 01:51 ET | 250000 | 0.0003 |
| 01:54 ET | 528720 | 0.0003 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Propanc Biopharma Inc | 237.0K | 0.0x | --- |
Myrexis Inc | 241.4K | 0.0x | --- |
RespireRx Pharmaceuticals Inc | 292.3K | 0.0x | --- |
Neximmune Inc | 338.7K | 0.0x | --- |
LadRx Corp | 365.0K | -0.1x | --- |
Molecular Pharmacology (USA) Ltd | 100.0K | -0.1x | --- |
Company Information
Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.
Contact Information
- Headquarters
- 302/6 Butler Street, CamberwellMELBOURNE, VIC, Australia 3124
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer, Chief Financial Officer, Treasurer, Director
- James Nathanielsz
- Director
- Julian Kenyon
- Director
- Josef Zelinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $237.0K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 789.9M |
Propanc Biopharma Inc does not pay a dividend. | |
Beta | 1.98 |
EPS | $-0.04 |
Book Value | $-0.01 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
